Join TScan Therapeutics for a virtual KOL event, featuring hematologist/oncologists Ran Reshef, MD, MSc (Columbia University Irving Comprehensive Cancer Center) and Monzr M. Al Malki, MD (City of Hope), to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT^®) and the Center for International Blood and Marrow Transplant Research (CIBMTR^®). The Tandem Meetings selected TScan’s abstract to receive a Best Abstracts Award.

The event will provide an in-depth review of the oral presentation related to TScan’s ongoing Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) (NCT05473910). The Company will also discuss the implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse.

A live question and answer session will follow the formal presentation.